Aquestive Therapeutics Inc.

06/10/2026 | Press release | Distributed by Public on 06/10/2026 14:02

Proxy Results (Form 8-K)

Item 5.07
Submission of Matters to a Vote of Security Holders
(a) Aquestive Therapeutics, Inc. (the "Company") held its 2026 Annual Meeting of Stockholders (the "Annual Meeting") on June 10, 2026.
(b) The final voting on each of the matters submitted to a vote of stockholders at the Annual Meeting are set forth below.
(1) The following director nominees were elected to serve as Class II members of the Board of Directors, to serve for a three-year term until the Company's 2029 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified:
Nominee Votes For Votes Against Votes Abstaining Broker Non-Votes
Gregory B. Brown, M.D. 41,373,033 - 1,222,711 37,465,582
John S. Cochran 36,914,899 - 5,680,845
Abigail L. Jenkins 39,094,166 - 3,501,578
(2) The proposal to approve, on a non-binding advisory basis, executive compensation was approved for the one year.
Votes For Votes Against Votes Abstaining Broker Non-Votes
37,798,609 3,192,381 1,604,754 37,465,582
(3) The appointment of KPMG LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2026 was ratified.
Votes For Votes Against Votes Abstaining
78,804,323 910,690 346,313
Aquestive Therapeutics Inc. published this content on June 10, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on June 10, 2026 at 20:03 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]